Immunic, Inc. (NASDAQ:IMUX - Free Report) - Stock analysts at HC Wainwright issued their Q4 2024 earnings estimates for shares of Immunic in a research note issued on Monday, November 25th. HC Wainwright analyst M. Caufield anticipates that the company will earn ($0.25) per share for the quarter. HC Wainwright has a "Buy" rating and a $10.00 price target on the stock. The consensus estimate for Immunic's current full-year earnings is ($0.93) per share.
Several other research analysts also recently commented on the stock. Leerink Partnrs raised shares of Immunic to a "strong-buy" rating in a research note on Monday, September 9th. StockNews.com cut Immunic from a "hold" rating to a "sell" rating in a research note on Monday, November 11th. B. Riley started coverage on Immunic in a research report on Tuesday, August 27th. They set a "buy" rating and a $6.00 target price for the company. Leerink Partners reissued an "outperform" rating and set a $5.00 price target on shares of Immunic in a research report on Monday, September 9th. Finally, EF Hutton Acquisition Co. I upgraded Immunic to a "strong-buy" rating in a report on Monday, September 16th. One analyst has rated the stock with a sell rating, five have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Immunic has a consensus rating of "Buy" and an average price target of $11.80.
View Our Latest Research Report on Immunic
Immunic Stock Performance
IMUX stock traded down $0.04 during midday trading on Tuesday, reaching $1.14. The company's stock had a trading volume of 635,129 shares, compared to its average volume of 624,246. Immunic has a 1 year low of $0.97 and a 1 year high of $2.11. The firm has a market capitalization of $102.69 million, a price-to-earnings ratio of -0.93 and a beta of 1.88. The stock has a fifty day simple moving average of $1.38 and a two-hundred day simple moving average of $1.34.
Institutional Investors Weigh In On Immunic
A number of large investors have recently bought and sold shares of IMUX. Virtu Financial LLC purchased a new stake in shares of Immunic in the third quarter worth about $50,000. Jane Street Group LLC boosted its position in Immunic by 121.4% in the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company's stock worth $116,000 after purchasing an additional 38,553 shares in the last quarter. State Street Corp grew its stake in shares of Immunic by 7.5% during the 3rd quarter. State Street Corp now owns 167,145 shares of the company's stock worth $276,000 after purchasing an additional 11,642 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Immunic by 70.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company's stock valued at $169,000 after purchasing an additional 42,383 shares in the last quarter. Finally, Ikarian Capital LLC lifted its stake in shares of Immunic by 258.3% in the 1st quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company's stock valued at $2,128,000 after purchasing an additional 1,162,378 shares during the period. Hedge funds and other institutional investors own 51.82% of the company's stock.
Insider Buying and Selling at Immunic
In related news, Director Richard Alan Rudick acquired 87,300 shares of the stock in a transaction dated Tuesday, November 12th. The stock was acquired at an average cost of $1.15 per share, for a total transaction of $100,395.00. Following the completion of the purchase, the director now owns 87,300 shares of the company's stock, valued at approximately $100,395. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 3.00% of the stock is owned by insiders.
Immunic Company Profile
(
Get Free Report)
Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Further Reading
Before you consider Immunic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunic wasn't on the list.
While Immunic currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
